Cost implications per patient per year by cost category, tumour type and country
Breast cancer | Prostate cancer | Other solid tumours | ||||
---|---|---|---|---|---|---|
Denosumab | Zoledronic acid* | Denosumab | Zoledronic acid* | Denosumab | Zoledronic acid* | |
Austria | ||||||
Cost of drugs | 4823 | 4212 | 4823 | 4418 | 4823 | 4323 |
Cost of administration/management | 143 | 514 | 143 | 540 | 143 | 528 |
Cost of SREs | 6100 | 7922 | 10856 | 13239 | 11198 | 13174 |
Total costs | 11066 | 12648 | 15821 | 18196 | 16164 | 18024 |
Total cost difference (denosumab vs ZA) | −1583 (12.5%) | −2375 (13.1%) | −1861(10.3%) | |||
Sweden | ||||||
Cost of drugs | 4607 | 4291 | 4607 | 4501 | 4607 | 4404 |
Cost of administration/management | 604 | 2143 | 604 | 2248 | 604 | 2199 |
Cost of SREs | 2564 | 3330 | 3601 | 4392 | 4016 | 4725 |
Total costs | 7775 | 9764 | 8812 | 11140 | 9228 | 11327 |
Total cost difference (denosumab vs ZA) | −1988 (20.4%) | −2328 (20.9%) | −2100 (18.5%) | |||
Switzerland | ||||||
Cost of drugs | 5882 | 4679 | 5882 | 4908 | 5882 | 4802 |
Cost of administration/management | 623 | 2041 | 623 | 2141 | 623 | 2095 |
Cost of SREs | 11204 | 14550 | 15091 | 18403 | 17095 | 20112 |
Total costs | 17709 | 21271 | 21596 | 25453 | 23600 | 27008 |
Total cost difference (denosumab vs ZA) | −3562 (16.7%) | −3857 (15.2%) | −3408 (12.6%) |
*Real world data on the frequency of administration of zoledronic acid were used.
All costs are in Euros.
SRE, skeletal-related event; vs, versus; ZA, zoledronic acid.